Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19
Takeda Pharmaceutical Company Limited will share with members of the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin…
Read More...
Read More...
